Table 3 Effect of Etpost (2 μg/ml) against the RISK/SAFE kinase inhibitors on arrhythmia score, VT, and VF incidence during the reperfusion phase of the IR model

IR (Con.)^@

3.23 ± 0.85

69.23

30.77

IPOST (Con.)

2.30 ± 0.75^*

50.00^*

10.00^*

Etpost (2 μg/ml)

4.33 ± 0.93^*

100.0^*

00.00^*

Etpost (2 μg/ml) + Wort

6.50 ± 0.83^*,#

100.0^*

66.67^*,#

Etpost (2 μg/ml) + PD

5.67 ± 0.34^*,#

66.67^#

100.0^*,#

Etpost (2 μg/ml) + AG

6.25 ± 0.75^*,#

50.0^*,#

100.0^*,#

Etpost (2 μg/ml) + HD

2.20 ± 0.17^*,#

100.0^*

00.000^*

IPOST + Wort

7.00 ± 0.00^*,&

100.0^*,&

100.0^*,&

IPOST + PD

7.00 ± 1.17^*,&

100.0^*,&

100.0^*,&

IPOST + AG

5.75 ± 1.25^*,&

50.00^*

50.00^*,&

IPOST + HD

3.00 ± 0.05^&

33.33^*,&

33.33^&